Clinical Outcomes and Predictors after Maintenance Discontinuation in MRD-Negative Transplant-Eligible Patients with Multiple Myeloma: A Single-Center Real-World Study

Abstract Purpose To evaluate clinical outcomes after maintenance therapy discontinuation in transplant-eligible multiple myeloma (MM) patients with measurable residual disease (MRD) negativity, identify predictors of post-discontinuation MRD resurgence, and assess salvage efficacy upon MRD recurrence. Methods This retrospective study enrolled 35 newly diagnosed MM patients treated at our center between January 2010 and January 2024. Patients received novel-agent induction, autologous stem cell transplantation, and maintenance therapy, which ceased after MRD negativity, were confirmed by multiparameter flow cytometry. The primary endpoint was MRD resurgence. Fine–Gray competing-risk regression was used to identify associated factors. Kaplan–Meier methods estimated treatment-free survival (TFS) and overall survival (OS). Results Median patient age was 53 years (range 35–67). Median duration from MRD negativity to maintenance cessation was 32.0 months; median post-discontinuation follow-up was 79.0 months. Fifteen patients (42.9%) developed MRD resurgence; 3- and 5-year cumulative incidence rates were 26.9% (95% CI 13.4–42.5%) and 37.4% (95% CI 21.1–53.8%), respectively. Using multivariable Fine-Grey analysis, high-risk cytogenetic abnormalities (HRCA)predicted higher MRD resurgence risk (HR 4.8, 95% CI 1.6–14.6, P = 0.005), whereas sustained MRD negativity ≥ 2 years before discontinuation reduced risk (HR 0.2, 95% CI 0.1–0.7, P = 0.012). Of 15 patients with MRD resurgence, 13 received salvage therapy and 10 (76.9%) regained MRD negativity. Median post-discontinuation TFS and OS were 67.3 and 80.0 months, respectively. Conclusion Maintenance discontinuation after MRD negativity is feasible in selected transplant-eligible MM patients. HRCA and sustained MRD negativity duration facilitate post-stop risk stratification. These exploratory findings require validation in larger multicenter cohorts.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11265931/v1
Primary Topic
Multiple Myeloma Research and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clinical Outcomes and Predictors after Maintenance Discontinuation in MRD-Negative Transplant-Eligible Patients with Multiple Myeloma: A Single-Center Real-World Study

Lifen Kuang, Meilan Chen, Xiaozhe Li, Beihui Huang et al.
7 links
Research Square
Multiple Myeloma Research and Treatments
preprint

Clinical Outcomes and Predictors after Maintenance Discontinuation in MRD-Negative Transplant-Eligible Patients with Multiple Myeloma: A Single-Center Real-World Study

Lifen Kuang, Meilan Chen, Xiaozhe Li, Beihui Huang, Juan Li
preprint en

Abstract

Abstract Purpose To evaluate clinical outcomes after maintenance therapy discontinuation in transplant-eligible multiple myeloma (MM) patients with measurable residual disease (MRD) negativity, identify predictors of post-discontinuation MRD resurgence, and assess salvage efficacy upon MRD recurrence. Methods This retrospective study enrolled 35 newly diagnosed MM patients treated at our center between January 2010 and January 2024. Patients received novel-agent induction, autologous stem cell transplantation, and maintenance therapy, which ceased after MRD negativity, were confirmed by multiparameter flow cytometry. The primary endpoint was MRD resurgence. Fine–Gray competing-risk regression was used to identify associated factors. Kaplan–Meier methods estimated treatment-free survival (TFS) and overall survival (OS). Results Median patient age was 53 years (range 35–67). Median duration from MRD negativity to maintenance cessation was 32.0 months; median post-discontinuation follow-up was 79.0 months. Fifteen patients (42.9%) developed MRD resurgence; 3- and 5-year cumulative incidence rates were 26.9% (95% CI 13.4–42.5%) and 37.4% (95% CI 21.1–53.8%), respectively. Using multivariable Fine-Grey analysis, high-risk cytogenetic abnormalities (HRCA)predicted higher MRD resurgence risk (HR 4.8, 95% CI 1.6–14.6, P = 0.005), whereas sustained MRD negativity ≥ 2 years before discontinuation reduced risk (HR 0.2, 95% CI 0.1–0.7, P = 0.012). Of 15 patients with MRD resurgence, 13 received salvage therapy and 10 (76.9%) regained MRD negativity. Median post-discontinuation TFS and OS were 67.3 and 80.0 months, respectively. Conclusion Maintenance discontinuation after MRD negativity is feasible in selected transplant-eligible MM patients. HRCA and sustained MRD negativity duration facilitate post-stop risk stratification. These exploratory findings require validation in larger multicenter cohorts.

Research Square
The First Affiliated Hospital, Sun Yat-sen University (CN)
Good health and well-being
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon